Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Science, Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286

This article has been corrected since it first published. This is to inform that co-author Wendy I White’s affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

Below is the updated information on the authors’ affiliation.

Kerry A Casey,¹ Xiang Guo,² Michael A Smith,¹ Shiliang Wang,² Dominic Sinibaldi,³ Miguel A Sanjuan,¹ Liangwei Wang,⁴ Gabor G Illei,⁵ Wendy I White²

¹Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA

²Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA

³Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA

⁴Biostatistics, MedImmune LLC, Gaithersburg, Maryland, USA

⁵Clinical Development, MedImmune LLC, Gaithersburg, Maryland, USA